Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Nektar Therapeutics (NKTR)

214 + Investors. Track Smart Money conviction in NKTR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +35
Streak
3Q ▲
Buyers last Q
64%

Smart Money Signals — NKTR

Based on 215 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added NKTR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
215 hedge funds hold NKTR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +36% more funds vs a year ago

fund count last 6Q
+57 new funds entered over the past year (+36% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 3 quarters from the low — a sharp move.
🟢

More buyers than sellers — 64% buying

150 buying85 selling
Last quarter: 150 funds were net buyers (71 opened a brand new position + 79 added to an existing one). Only 85 were sellers (49 trimmed + 36 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new NKTR position: 27 → 63 → 65 → 71. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

48% of holders stayed for 2+ years

■ 48% conviction (2yr+) ■ 18% medium ■ 33% new
104 out of 215 hedge funds have held NKTR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +152% but shares only +52% — price-driven

Value
+152%
Shares
+51%
Last quarter: the total dollar value of institutional holdings rose +152%, but actual share count only changed +52%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

32 → 27 → 63 → 65 → 71 new funds/Q
New funds entering each quarter: 27 → 63 → 65 → 71. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 60% veterans vs 35% newcomers

■ 60% veterans ■ 6% 1-2yr ■ 35% new
Entry-cohort mix of 226 holders: 135 (60%) are 2+ year veterans, 13 entered 1–2 years ago, and 78 (35%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 34% AUM from major funds

34% from top-100 AUM funds
33 of 214 holders rank in the top 100 by AUM, accounting for 34% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.7
out of 10
Moderate Exit Risk
Exit risk score 4.7/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — NKTR

In 2026 Q1, 150 hedge funds were net buyers of NKTR (71 opened a new position, 79 added to an existing one), while 85 reduced or exited (49 trimmed, 36 sold completely) — a 64% buyer ratio, indicating clear institutional accumulation. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 34% of total institutional value in NKTR is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +35 funds (more new holders than closures). Total institutional holders: 215.

Hedge Fund Ownership: NKTR

How many hedge funds hold NKTR — quarterly history vs. share price
Quarterly hedge fund ownership of NKTR vs. share price

Market Analysis: NKTR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: NKTR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Nektar Therapeutics (NKTR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much NKTR has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 85d ago
NKTR
-5.9%
XLV
+2.8%

NKTR outperformed XLV by -8.7% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 40d ago
NKTR
-4.1%
XLV
+3.9%

Since the filing became public, NKTR outperformed XLV by -8.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

23 top-rated funds 6 high-conviction
Consensus
6.0
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: NKTR
214 + Investors

Track Smart Money conviction in NKTR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 214 180 18.89%
13F Shares 28M 19M 51.71%
Total Value $1.98B $784M 152.2%
New Positions 71 65 +6
Increased Positions 74 52 +22
Closed Positions 37 34 +3
Reduced Positions 49 43 +6
Total Calls 7 8 -12.5%
Total Puts 5 6 -16.67%
PUT/CALL Ratio 0.71 0.75 Neutral

Statistics: NKTR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

214 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NKTR. Verified SEC 13F-HR filings.

QUARTER:
Top 25 NKTR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 22nw, LP 13.86% 281,115 $20.2M
2 Prosight Management, LP 8.67% 735,000 $52.9M
3 Bvf Inc/Il 5.87% 2,559,595 $184.2M
4 Great Point Partners LLC 5.23% 316,453 $22.8M
5 Act Capital Management, LLC 4.01% 70,900 $5.1M
6 Monashee Investment Management LLC 3.91% 100,000 $7.2M
7 Squadron Capital Management LLC 3.30% 125,000 $9.0M
8 DAFNA Capital Management LLC 2.70% 165,178 $11.9M
9 Patient Square Capital LP 2.68% 210,000 $15.1M
10 Stonepine Capital Management, LLC 2.45% 85,000 $6.1M
11 Creek Drive Management Group LLC 2.07% 126,400 $9.1M
12 Two Seas Capital LP 1.97% 1,959,178 $141.0M
13 Deuterium Capital Management, LLC 1.51% 18,000 $1.3M
14 KVP Capital Advisors, LP 1.45% 26,900 $1.9M
15 Bronte Capital Management Pty Ltd. 1.44% 202,500 $14.6M
16 Tetragon Partners GP Ltd 1.44% 103,037 $7.4M
17 Bronte Capital Management Pty Ltd. 1.41% 198,256 $14.3M
18 Sofinnova Investments, Inc. 1.39% 509,546 $36.7M
19 Birchview Capital, LP 1.27% 31,000 $2.2M
20 Moody Aldrich Partners LLC 1.16% 89,527 $6.4M
21 Fifth Lane Capital, LP 1.05% 12,000 $863K
22 Iridian Asset Management LLC/Ct 0.91% 31,320 $2.3M
23 Emerald Advisers, LLC 0.90% 394,604 $28.4M
24 Emerald Mutual Fund Advisers Trust 0.89% 256,106 $18.4M
25 Creek Drive Management Group LLC 0.82% 50,000 $3.6M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Nektar Therapeutics (NKTR)

What does the Smart Money Trend signal show for NKTR?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added NKTR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for NKTR?

More buyers than sellers — 64% buying: Last quarter: 150 funds were net buyers (71 opened a brand new position + 79 added to an existing one). Only 85 were sellers (49 trimmed + 36 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for NKTR holders?

Strong quality — 34% AUM from major funds: 33 of 214 holders rank in the top 100 by AUM, accounting for 34% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held NKTR?

48% of holders stayed for 2+ years: 104 out of 215 hedge funds have held NKTR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Nektar Therapeutics (NKTR) following the 2026 Q1 hedge fund 13F filings?

As of today, NKTR has moved -4.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -8.0%. Since the quarter end (March 31, 2026), NKTR has gained -5.9% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →